HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents.

AbstractBACKGROUND:
Limited data are available on characteristics of viral encephalitis in patients after allogeneic stem cell transplantation.
DESIGN AND METHODS:
We analyzed 2,628 patients after allogeneic stem cell transplantation to identify risk factors and characteristics of viral encephalitis.
RESULTS:
Viral encephalitis occurred in 32 patients (1.2%, 95% confidence interval 0.8%-1.6%) and was associated with the use of OKT-3 or alemtuzumab for T-cell depletion (P < 0.001) and an increased mortality (P = 0.011) in comparison to patients without viral encephalitis. Detected viruses included human herpesvirus-6 (28%), Epstein-Barr virus (19%), herpes simplex virus (13%), JC virus (9%), varicella zoster virus (6%), cytomegalovirus (6%) and adenovirus (3%). More than one virus was identified in 16% of the patients. The median onset time was 106 days after allogeneic stem cell transplantation for the total group of 32 patients, but onset times were shortest in those with human herpesvirus-6 encephalitis and longest in those with JC virus-associated progressive multifocal leukoencephalopathy. The probability of a sustained response to treatment was 63% (95% confidence interval 44%-82%) with a median survival of 94 (95% confidence interval 36-152) days after onset, but significant variation was found when considering different causative viruses. Patients with herpes simplex virus encephalitis had the most favorable outcome with no encephalitis-related deaths.
CONCLUSIONS:
The use of OKT-3 or alemtuzumab for in vivo T-cell depletion is associated with an increased risk of viral encephalitis after allogeneic stem cell transplantation. Different viruses are frequently associated with distinct characteristics such as onset time, response to treatment and outcome.
AuthorsMartin Schmidt-Hieber, Julie Schwender, Werner J Heinz, Tatjana Zabelina, Jörn S Kühl, Sabine Mousset, Silke Schüttrumpf, Christian Junghanss, Gerda Silling, Nadezda Basara, Stefan Neuburger, Eckhard Thiel, Igor W Blau
JournalHaematologica (Haematologica) Vol. 96 Issue 1 Pg. 142-9 (Jan 2011) ISSN: 1592-8721 [Electronic] Italy
PMID20851868 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Antiviral Agents
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Alemtuzumab
Topics
  • Adolescent
  • Adult
  • Aged
  • Alemtuzumab
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Antiviral Agents (therapeutic use)
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Encephalitis, Viral (drug therapy, etiology)
  • Female
  • Graft vs Host Disease (etiology)
  • Hematologic Neoplasms (therapy)
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Infant
  • Lymphocyte Depletion
  • Male
  • Middle Aged
  • Muromonab-CD3 (therapeutic use)
  • Retrospective Studies
  • Survival Rate
  • Transplantation, Homologous
  • Treatment Outcome
  • Virus Activation
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: